Dynamiker Biotechnology (Tianjin) Co., Ltd.

Industry News >> News >> Home

News

The Official QR Code

Industry News

Europe release “Chronic Pulmonary Aspergillosis (CPA): Rationale and Clinical Guideline for Diagnosis and Management”

AddTime:2016/7/7 14:17:32    Source:Dynamiker Biotechnology (Tianjin) Co., Ltd.    Views:841


Recently, clinical guideline for diagnosis and management of CPA is released, by the leading of prof. David Denning, president of global action fund for fungal infections (GAFFI) from education and research centre of University Hospital of South Manchester, and with the cooperation of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), European Confederation of Medical Mycology (ECMM) and the European Respiratory Society (ERS). 

Recent years, CPA increases in prevalence and becomes the second major pulmonary fungal infectious disease after candidiasis, leading to great suffering in patients. The burden of CPA in Europe is estimated to be 0.24 million and the global burden is as much as 3 million.

The guideline involves detailed description of CPA’s critical features and provides integrated treatment recommendations. It is a new breakthrough of early rapid diagnosis and effective treatment of CPA.